Aiming for larger rare disease market, BioMarin buys Alesta program

In its acquisition of Alesta, BioMarin sees the addition of a promising oral therapy for hypophosphatasia as well as an avenue toward commercializing an asset in what could become its largest market yet for a rare disease.

The deal is the latest under the leadership of CEO Alexander Hardy and EVP and CBO James Sabry. The latter told BioCentury last year that BioMarin’s team expects to continue reshaping the company through a “continuous” series of deals, including its acquisition of Amicus Therapeutics Inc. for $4.8 billion...